Clinical Trial Update: SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SBRT/LDRT with camrelizumab and apatinib in metastatic non-small cell lung cancer patients previously treated with PD-1/PD-L1 inhibitor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• SBRT/LDRT

Snippet

Sponsor: Wuhan University | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN